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The human immune system is supposed to defend 
our organism from disease-causing agents such as viruses 
and bacteria. It performs this task using different strategies 
from directly killing the pathogens to reducing their viability 
(Nicholson, 2016). For instance, it is known that one member 
of the double-domain cytidine deaminase APOBEC, namely 
APOBEC3G, inhibits a broad range of retroviruses, such 
as HIV, by hypermutating their sequences (Mangeat et al., 
2003). The basic idea is to produce a premature stop-codon 
or modify some important protein to the virus propagation 
cycle. There are at least two gene families that edit RNA, 
DNA or both (Navaratnam and Sarwar, 2006; Avesson and 
Barry, 2014; Chemudupati et al., 2019), which suggests that 
the virus sequence hypermutation (VSH) mechanism may 
be an evolutionary defense tool (Vieira and Soares, 2013). 
However, to the best of our knowledge, the scientific 
community has failed to realize that the VSH mechanism may 
be an important player in the co-evolution of viruses and hosts 
(Kerr et al., 2017), producing attenuated virus strains that 
eventually become dominant. For instance, some mutations 
may impair the viral pathogenicity. Nothing prevents these 
mutated viruses to leave the host and, because infected people 
do not get badly ill to propagate faster than the wild type. In a 
real-life situation, these attenuated viruses could act just like 
a vaccine, conferring immunity to the population. Perhaps, 
the VSH mechanism evolutionary function is to generate, 
within each infected cell, i.e., in a massive parallel production, 
mutated strains that could train the immune system against 
the virulent wild type. If this conjecture proves correct, then 
the immune system has a two-fold mission: to safeguard our 
organism by destroying the threatening agents and to protect 
our species, acting like a powerful vaccine factory. But how 
realistic is this speculation?
Since its very beginning in Wuhan, the SARS-CoV-2 
virus has been sequenced hundreds of thousands of times, and 
new sequences are still being deposited every day. Thousands 
of single nucleotide polymorphisms, called SNPs, had been 
reported, and those SNPs helped to trace back the virus’ 
geographic origin and its probable starting date (van Dorp et 
al., 2020a). Of course, the very existence of SNPs is consistent 
with the viruses “quasispecies” theory, which states that high 
mutation rates are expected to occur just by chance (Crotty 
et al., 2001). Yet, those mutations could also be a sign of the 
action of the VSH mechanism. Despite their different etiology, 
both processes can co-exist: the virus evolution versus the 
VSH mechanism. 
Is there any evidence that the VSH mechanism is 
mutating the SARS-CoV-2 virus? The first evidence that a 
host-dependent RNA editing mechanism was mutating the 
SARS-CoV-2 sequence appeared as soon as March 3rd 2020. 
Dr. Conticello’s group identified signatures of RNA editing, 
namely, Adenosine-to-Uracil changes from ADAR deaminases 
and Cytosine-to-Uracil changes from APOBEC ones (Di 
Giorgio et al., 2020). This amazing finding was independently 
confirmed by Dr. Balloux’s group which analyzed 46,723 
SARS-CoV-2 genomes isolated from patients worldwide, in 
their own words: “we observed an enrichment in CCA and TCT 
3-mers containing a variable base in their central position, 
which are known targets for the human APOBEC RNA-editing 
enzyme family” (van Dorp et al., 2020b). The authors of 
those two manuscripts did not draw the straightforward and 
bold conclusion of their own work. It was Dr. Simmonds 
(Simmonds, 2020) who dared to uphold that: “the finding that 
a large proportion of sequence change in SARS-CoV-2 in the 
initial months of the pandemic comprised C→U mutations in 
a host APOBEC-like context provides evidence for a potent 
host-driven antiviral editing mechanism against coronaviruses 
more often associated with antiretroviral defense.” This last 
statement extends the VSH mechanism beyond retroviruses, 
but it fails to acknowledge that it may be an important player 
in the co-evolution of viruses and hosts.
There are three main objections that should be addressed. 
The first is that most of the immune system induced mutations 
are silent, i.e., they preserve protein sequences (van Dorp et 
al., 2020a), and, unfortunately, the scientific community is 
looking for non-silent mutations that could produce either 
more virulent or attenuated strains. However, silent mutations 
have at least two advantages over non-silent ones from an 
immunological point of view: (1) they, by definition, preserve 
the protein sequence which could be used to train the immune 
system against the wild type, and (2) they may “decrease 
translational load on the host per unit of expression” (Cheng 
et al., 2020) which could, at least in principle, reduce SARS-
CoV-2 virulence. 
The second concern is that the SARS-CoV-2 virus has not 
changed significantly. Despite thousands of mutations having 
been reported so far, the average pairwise difference (APD) 
between any two SARS-CoV-2 genomes is 9.6 SNPs (van Dorp 
et al., 2020a). Considering that the SARS-CoV-2 reference 
genome (NC_045512.2) has 29,903 nucleotides, the APD is 
less than 0.033%, which confirms that the SARS-Cov-2 virus 
is almost unchanged. Nevertheless, the question that begs to 
be answered is: how many silent mutations are necessary to 
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affect protein expression or function? Surprisingly enough, 
the answer to this important question is just one mutation 
(Kimchi-Sarfaty et al., 2007). There are also several papers 
discussing how important a few silent mutations can be to 
protein expression and function (Komar, 2007; Harrigan et al., 
2008; Plotkin and Kudla, 2011; Sauna and Kimchi-Sarfaty, 
2011). Therefore, silent mutations induced by the immune 
system should at least be taken seriously. 
Maybe, a subset of those silent mutations induced by 
the immune system may produce an attenuated SARS-CoV-2 
strain, which is the last issue I will address. Recently, Dr. 
Ozer’s group has reported a clade of SARS-CoV-2 associated 
with lower viral loads in patients (Lorenzo-Redondo et al., 
2020). As expected, the authors emphasize the role of a non-
silent mutation, namely D614G, within the spike protein. 
However, they also reported two silent mutations C→U. 
The first occurred within the Nsp14 protein (orf1ab, position 
18060) and helped to distinguish the Clade 2, supposedly with 
lower viral load, from Clade 3. The second was within the 
Nsp3 protein (Orf1a, position 3037) and helped to sort out 
Clade 2 from Clade 1. As the authors did not determine causal 
relationships between mutations and phenotype, it is possible 
that those silent mutations may play an important role as well; 
otherwise, Clade 3 should have presented a lower viral load 
because it also shared the same non silent spike mutation.
This letter intends to call attention to the question 
whether the immune system is also a powerful vaccine factory. 
It goes without saying that the “vaccine factory” wording is 
just a metaphor; it does not imply the existence of a targeted 
goal. There is already sufficient evidence that our immune 
system is actively mutating the SARS-CoV-2 sequence. No 
one fully understands the impact to the virus cycle of those 
mutations, particularly the silent ones. It is necessary to probe 
and study the relationship between those immune system 
induced mutations and the viral cycle. Our technology is 
sufficiently advanced to address the problem. We are just 
missing to put together a multidisciplinary research group 
to work on it. The paradigm of vaccine production (Plotkin, 
2009) needs to evolve to minimize the time taken and to 
reduce the costs. Throughout the centuries, men have always 
looked at nature for inspiration. If the VSH mechanism creates 
natural vaccines, then what can we learn from it? Are the 
silent mutations the best way to produce attenuated viruses? 
Is it possible to emulate it ‘in vitro’? Can we use the virus' 
own capsid to deliver the vaccines? 
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